ALLO
A biotech adrenaline shot
Allogene Therapeutics didn’t just have a good Monday — it had the kind of Monday that makes a stock chart look like it drank three espressos. Shares jumped 36% after the company said interim data from its pivotal ALPHA3 trial showed cemacabtagene ansegedleucel, or cema-cel, achieved 58.3% minimal residual disease clearance versus 16.7% in the observation arm.
Why investors care
This is not some academic footnote. ALPHA3 is a pivotal study, which means the market is treating it like a potential path to an actual product story, not just another science fair poster. The endpoint here is event-free survival, and the trial is built to see whether cema-cel can cut the risk of bad outcomes like disease progression, new therapy, or death.
The long road ahead
The trial is enrolling across more than 60 sites and is expected to bring in about 220 patients. That enrollment is slated to finish by year-end 2027, with an interim EFS readout expected in mid-2027 and the big primary analysis landing in mid-2028. In biotech time, that’s basically tomorrow and also a geological era.
Big picture
For now, the headline is simple: the market liked the signal, and liked it a lot. But as always with biotech, a nice interim readout is the opening act — not the final credits.